<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; AEZS</title>
	<atom:link href="http://www.stockbloghub.com/tag/aezs/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(KERX) Keryx Biopharmaceuticals Cancer Drug Impresses</title>
		<link>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474</link>
		<comments>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474#comments</comments>
		<pubDate>Sat, 03 Oct 2009 22:08:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aeterna Zentaris Inc]]></category>
		<category><![CDATA[AEZS]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[RCC]]></category>
		<category><![CDATA[Small Cap Premium & Dividend Income Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16474</guid>
		<description><![CDATA[Last week, Keryx Biopharmaceuticals, Inc. (KERX) announced that its renal cancer drug KRX-0401 (perifosine) met both primary and secondary endpoints in a mid-stage trial. KRX-0401 is in-licensed by Keryx from Aeterna Zentaris Inc. (AEZS) in the US, Canada and Mexico. The data was presented at the eighth International Kidney Cancer Symposium in Chicago. The candidate demonstrated efficacy, safety and tolerability in metastatic renal cell carcinoma (RCC) patients whose disease progressed after failing treatment with both a VEGF (vascular endothelial growth factor) receptor inhibitor and an mTOR (mammalian target of rapamycin) inhibitor. Even though the drug was well-tolerated, the most common adverse events were gastrointestinal discomfort and fatigue. RCC is the most common of all kidney tumors, accounting for 85% of the cases. The advanced form of the disease is resistant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

